[Influence of omega-3 fatty acids on lipid metabolism in children with steroid sensitive nephrotic syndrome].
Changes in lipid metabolism is one of the most important features of steroid sensitive nephrotic syndrome. Increased serum lipid level not always is connected with disease activity and sometimes may persist for long time, especially in frequently relapsing nephrotic syndrome. Hyperlipidemia and dyslipidemia are connected with cardiovascular diseases and development of glomerulosclerosis. Omega-3 (omega-3) polyunsaturated fatty acids have positive influence on lipid metabolism, diminishing hypercoagulation and a risk of cardiovascular diseases. The aim of this study was to examine influence of omega-3 polyunsaturated fatty acids on lipid disturbances in children with steroid sensitive nephrotic syndrome. Forty-eight patients were included in the study; 24 of them were treated with prednisolone (control group) and 24 were treated with prednisolone and fish oil (6 mg/day) along with symptomatic therapies. Serum lipid profile and spectrum of fatty acids before treatment and three months after start of the treatment were evaluated. Before treatment, contents of serum fatty acids and lipids did not differ between the groups. The study showed decrease in serum triglycerides (p<0.06) and omega-6 polyunsaturated fatty acids (p<0.02), increase in concentration of omega-3 polyunsaturated fatty acids and the ratio of 20:5 omega-3/20: omega-6 (eicosapentaenoic/arachidonic acids) (p<0.001). Cholesterol, HDL-Ch, LDL-Ch concentrations did not change under the treatment with fish oil. We conclude that fish oil might be useful as an agent normalising lipid metabolism in children with steroid sensitive nephrotic syndrome.
Cerkauskiene
Rimante
R
Center of Pediatrics, Vilnius University Children's Hospital, Vilnius, Lithuania. rimantec@yahoo.com
Kaminskas
Arvydas
A
Kaltenis
Petras
P
Vitkus
Dalius
D
D000293:Adolescent; D000367:Age Factors; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D002784:Cholesterol / Q000097:blood; D003627:Data Interpretation, Statistical; D015525:Fatty Acids, Omega-3 / Q000494:pharmacology / Q000627:therapeutic use*; D005395:Fish Oils / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy / Q000209:etiology; D050356:Lipid Metabolism / Q000187:drug effects*; D008055:Lipids / Q000097:blood; D009404:Nephrotic Syndrome / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D018579:Patient Selection; D011239:Prednisolone / Q000008:administration & dosage / Q000627:therapeutic use*; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood
D000893:Anti-Inflammatory Agents; D015525:Fatty Acids, Omega-3; D005395:Fish Oils; D008055:Lipids; D014280:Triglycerides; D002784:Cholesterol; D011239:Prednisolone